200 related articles for article (PubMed ID: 15655558)
1. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer.
Gowardhan B; Douglas DA; Mathers ME; McKie AB; McCracken SR; Robson CN; Leung HY
Br J Cancer; 2005 Jan; 92(2):320-7. PubMed ID: 15655558
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
Heer R; Douglas D; Mathers ME; Robson CN; Leung HY
J Pathol; 2004 Dec; 204(5):578-86. PubMed ID: 15538740
[TBL] [Abstract][Full Text] [Related]
3. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.
Sahadevan K; Darby S; Leung HY; Mathers ME; Robson CN; Gnanapragasam VJ
J Pathol; 2007 Sep; 213(1):82-90. PubMed ID: 17607666
[TBL] [Abstract][Full Text] [Related]
4. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
5. Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries.
Hughes SE
Cardiovasc Res; 1996 Sep; 32(3):557-69. PubMed ID: 8881516
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-IIIc and FGFR3 are not.
Boget S; Cereser C; Parvaz P; Leriche A; Revol A
Eur J Endocrinol; 2001 Sep; 145(3):303-10. PubMed ID: 11517011
[TBL] [Abstract][Full Text] [Related]
7. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride.
Sáez C; González-Baena AC; Japón MA; Giráldez J; Segura DI; Rodríguez-Vallejo JM; González-Esteban J; Miranda G; Torrubia F
Prostate; 1999 Jul; 40(2):83-8. PubMed ID: 10386468
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of FGF-receptors expressed by stromal and epithelial cells cultured from normal and hyperplastic prostates.
Story MT; Hopp KA; Molter M; Meier DA
Growth Factors; 1994; 10(4):269-80. PubMed ID: 7528517
[TBL] [Abstract][Full Text] [Related]
9. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype.
Murphy T; Darby S; Mathers ME; Gnanapragasam VJ
J Pathol; 2010 Mar; 220(4):452-60. PubMed ID: 19960500
[TBL] [Abstract][Full Text] [Related]
10. Differential distribution of fibroblast growth factor receptors (FGFRs) on foveal cones: FGFR-4 is an early marker of cone photoreceptors.
Cornish EE; Natoli RC; Hendrickson A; Provis JM
Mol Vis; 2004 Jan; 10():1-14. PubMed ID: 14737068
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated expression of a soluble fibroblast growth factor receptor inhibits in vitro growth of prostate DU145 cells.
Gowardhan B; West AF; Robson CN; Leung HY
Prostate; 2004 Sep; 61(1):50-9. PubMed ID: 15287093
[TBL] [Abstract][Full Text] [Related]
12. [Studies on the expression of fibroblast growth factors and fibroblast growth factor receptors in human prostate cancer].
Takahashi H
Nihon Hinyokika Gakkai Zasshi; 1998 Oct; 89(10):836-45. PubMed ID: 9844400
[TBL] [Abstract][Full Text] [Related]
13. Exogenous fibroblast growth factors maintain viability, promote proliferation, and suppress GADD45alpha and GAS6 transcript content of prostate cancer cells genetically modified to lack endogenous FGF-2.
Shain SA
Mol Cancer Res; 2004 Nov; 2(11):653-61. PubMed ID: 15561781
[TBL] [Abstract][Full Text] [Related]
14. [Expression and its significance of b-FGF in human benign prostatic hyperplasia and prostatic carcinoma tissues].
Wang FL; Wang H; Qin WJ; Wu GJ; Zhang G; Li KN
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Mar; 20(2):203-5. PubMed ID: 15191726
[TBL] [Abstract][Full Text] [Related]
15. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.
West AF; O'Donnell M; Charlton RG; Neal DE; Leung HY
Br J Cancer; 2001 Aug; 85(4):576-83. PubMed ID: 11506499
[TBL] [Abstract][Full Text] [Related]
16. Keratinocyte growth factor expression in hormone insensitive prostate cancer.
Leung HY; Mehta P; Gray LB; Collins AT; Robson CN; Neal DE
Oncogene; 1997 Aug; 15(9):1115-20. PubMed ID: 9285567
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
Bao Y; Gabrielpillai J; Dietrich J; Zarbl R; Strieth S; Schröck F; Dietrich D
Clin Epigenetics; 2021 Dec; 13(1):228. PubMed ID: 34933671
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor expression in the postnatal growth plate.
Lazarus JE; Hegde A; Andrade AC; Nilsson O; Baron J
Bone; 2007 Mar; 40(3):577-86. PubMed ID: 17169623
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation.
Rosini P; Bonaccorsi L; Baldi E; Chiasserini C; Forti G; De Chiara G; Lucibello M; Mongiat M; Iozzo RV; Garaci E; Cozzolino F; Torcia MG
Prostate; 2002 Dec; 53(4):310-21. PubMed ID: 12430142
[TBL] [Abstract][Full Text] [Related]
20. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
